Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs ...
As publishers and research platforms such as Reaxys and Springer Nature build application programming interface (API) access ...
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, ...
Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied ...
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor ...
Access Part 1 of this interview in which Scarboro explains why real-world usability belongs at product definition. Access ...
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a ...
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma ...
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label ...
Thermo Fisher Scientific announced it is showcasing new and expanded services at CPHI Milan, which is happening from October 6-8, 2026. The company will be presenting new drug dev ...
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results